mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2020-1-125-128mrj-1003Research ArticleИНФОРМАЦИЯINFORMATIONРезолюция Совета экспертов, посвященного теме «Интерстициальные заболевания легких при системной склеродермии» (14 октября 2019 г., Москва)The resolution of the Expert Council on Interstitial Lung Diseases in Systemic Scleroderma (Moscow, October 14, 2019)АвдеевС. Н.AvdeevS. N.

119991, Москва, ул. Трубецкая, 8, стр. 2

8, Trubetskaya St., Build. 2, Moscow 119991

АнаньеваЛ. П.AnanyevaL. P.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ЖиляевЕ. В.ZhilyaevE. V.

125993, Москва, ул. Баррикадная, 2/1, стр. 1

2/1, Barrikadnaya St., Build. 1, Moscow 125993

ЗоноваЕ. В.ZonovaE. V.

630091, Новосибирск, Красный проспект, 52

52, Krasnyi Prospect, Novosibirsk 630091

КлименкоА. А.KlimenkoA. A.

117997, Москва, ул. Островитянова, 1

1, Ostrovityanov St., Moscow 117997

КоневаО. А.KonevaO. A.

115522, Москва, Каширское шоссе, 34А

V.A. Nasonova Research Institute of Rheumatology

ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А;

125993, Москва, ул. Баррикадная, 2/1, стр. 1

V.A. Nasonova Research Institute of Rheumatology;

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

ПершинаЕ. С.PershinaE. S.

119049, Москва, Ленинский проспект, 8

8, Leninsky Prospect, Moscow 119049

СтремоуховА. А.StremoukhovA. A.

125993, Москва, ул. Баррикадная, 2/1, стр. 1

Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

ТерпигоревС. А.TerpigorevS. A.

129110,  Москва, ул. Щепкина, 61/2, корп. 1

61/2, Shchepkin St., Build. 1, Moscow 129110

ТюринИ. Е.TyurinI. E.

630091, Новосибирск, Красный проспект, 52

52, Krasnyi Prospect, Novosibirsk 630091

ШостакН. А.ShostakN. A.

117997, Москва, ул. Островитянова, 1

1, Ostrovityanov St., Moscow 117997

ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Russian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian FederationФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава РоссииРоссияNovosibirsk State Medical University, Ministry of Health of RussiaRussian FederationФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian FederationГБУЗ г. Москвы «Городская клиническая больница №1 им. Н.И. Пирогова» Департамента здравоохранения г. МосквыРоссияN.I. Pirogov City Clinical Hospital One, Moscow Healthcare DepartmentRussian Federationфакультет усовершенствования врачей ГБУЗ МО «Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского»РоссияFaculty for Postgraduate Training of Physicians, M.F. Vladimirsky Moscow Regional Research Clinical InstituteRussian Federation202022032020141125128Copyright © Авдеев С.Н., Ананьева Л.П., Жиляев Е.В., Зонова Е.В., Клименко А.А., Конева О.А., Лила А.М., Першина Е.С., Стремоухов А.А., Терпигорев С.А., Тюрин И.Е., Шостак Н.А., 20202020Авдеев С.Н., Ананьева Л.П., Жиляев Е.В., Зонова Е.В., Клименко А.А., Конева О.А., Лила А.М., Першина Е.С., Стремоухов А.А., Терпигорев С.А., Тюрин И.Е., Шостак Н.А.Avdeev S.N., Ananyeva L.P., Zhilyaev E.V., Zonova E.V., Klimenko A.A., Koneva O.A., Lila A.M., Pershina E.S., Stremoukhov A.A., Terpigorev S.A., Tyurin I.E., Shostak N.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1003

В заключении Совета экспертов представлены результаты обсуждения вопросов диагностики и терапии интерстициальных заболеваний легких при системной склеродермии. Причиной данного обсуждения послужило появление новых данных о применении препарата нинтеданиб у этой категории пациентов.

The conclusion of the Expert Council presents the results of discussing the diagnosis and therapy of interstitial lung diseases in systemic scleroderma. The reason for this discussion was the emergence of new data on the use of nintedanib in this category of patients.

Статья спонсируется компанией ООО «Берингер Ингельхайм».ReferencesVan den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747-55. doi: 10.1136/annrheumdis-2013-204424Van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747-55. doi: 10.1136/annrheumdis-2013-204424Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007;66: 754-63. doi: 10.1136/ard.2006.062901Walker UA, Tyndall A, Czirjak L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis. 2007;66: 754-63. doi: 10.1136/ard.2006.062901Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 2016;11(10):e0163894. doi: 10.1371/journal.pone.0163894Jaeger VK, Wirz EG, Allanore Y, et al. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: a longitudinal EUSTAR study. PLoS One. 2016;11(10):e0163894. doi: 10.1371/journal.pone.0163894Frantz C, Avouac J, Distler O, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey. Semin Arthritis Rheum. 2016;46:115-23. doi: 10.1016/j.semarthrit.2016.02.005Frantz C, Avouac J, Distler O, et al. Impaired quality of life in systemic sclerosis and patient perception of the disease: a large international survey. Semin Arthritis Rheum. 2016;46:115-23. doi: 10.1016/j.semarthrit.2016.02.005Fischer A, Zimovetz E, Ling C, et al. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev. 2017;16:1147-54. doi: 10.1016/j.autrev.2017.09.010Fischer A, Zimovetz E, Ling C, et al. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev. 2017;16:1147-54. doi: 10.1016/j.autrev.2017.09.010Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76: 1897-905. doi: 10.1136/annrheumdis-2017- 211448Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis. 2017;76: 1897-905. doi: 10.1136/annrheumdis-2017- 211448Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354: 2655-66. doi: 10.1056/NEJMoa055120Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354: 2655-66. doi: 10.1056/NEJMoa055120Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708-19. doi: 10.1016/S2213-2600(16)30152-7Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomized controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708-19. doi: 10.1016/S2213-2600(16)30152-7Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015; 45:1434-45. doi: 10.1183/09031936.00174914Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015; 45:1434-45. doi: 10.1183/09031936.00174914Чучалин АГ, Авдеев СН, Айсанов ЗР и др. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. Пульмонология. 2016;26(4):399-419. [Chuchalin AG, Avdeev SN, Aysanov ZR, et al. Diagnosis and treatment of idiopathic pulmonary fibrosis. Federal clinical guidelines. Pul'monologiya. 2016;26(4):399-419 (In Russ.)].Чучалин АГ, Авдеев СН, Айсанов ЗР и др. Диагностика и лечение идиопатического легочного фиброза. Федеральные клинические рекомендации. Пульмонология. 2016;26(4):399-419. [Chuchalin AG, Avdeev SN, Aysanov ZR, et al. Diagnosis and treatment of idiopathic pulmonary fibrosis. Federal clinical guidelines. Pul'monologiya. 2016;26(4):399-419 (In Russ.)].Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365:1079-87. doi: 10.1056/NEJMoa1103690Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365:1079-87. doi: 10.1056/NEJMoa1103690Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2071-82. doi: 10.1056/NEJMoa1402584Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370:2071-82. doi: 10.1056/NEJMoa1402584Kikuchi K, Kadono T, Ihn H, et al. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1. J Invest Dermatol. 1995; 105:128-32. doi: 10.1111/1523-1747.ep12313452Kikuchi K, Kadono T, Ihn H, et al. Growth regulation in scleroderma fibroblasts: increased response to transforming growth factor-beta 1. J Invest Dermatol. 1995; 105:128-32. doi: 10.1111/1523-1747.ep12313452Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63:783-94. doi: 10.1002/art.30159Hsu E, Shi H, Jordan RM, et al. Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension. Arthritis Rheum. 2011;63:783-94. doi: 10.1002/art.30159Lam AP, Flozak AS, Russell S, et al. Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol. 2011;45:915-22. doi: 10.1165/rcmb.2010-0113OCLam AP, Flozak AS, Russell S, et al. Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol. 2011;45:915-22. doi: 10.1165/rcmb.2010-0113OCHuang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76: 1941-8. doi: 10.1136/annrheumdis-2016- 210823Huang J, Maier C, Zhang Y, et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann Rheum Dis. 2017;76: 1941-8. doi: 10.1136/annrheumdis-2016- 210823Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518-28. doi: 10.1056/NEJM oa1903076Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518-28. doi: 10.1056/NEJM oa1903076Flaherty KR, Wells AU, Vincent Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019; 381:1718-27. doi: 10.1056/NEJMoa1908681Flaherty KR, Wells AU, Vincent Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019; 381:1718-27. doi: 10.1056/NEJMoa1908681

The authors declare that there are no conflicts of interest present.